Reports

Drug name	NICE TAs	Comments
Avalglucosidase	TA821: Avalglucosidase alfa for treating Pompe disease
Avatrombopag	TA626 - Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Avatrombopag (Doptelet®)	TA853 - Avatrombopag for treating primary chronic immune thrombocytopenia TA626 - Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Avelumab (Bavencio®)	TA517 - Avelumab for treating metastatic Merkel cell carcinoma TA644 - Avelumab with axitinib for untreated advanced renal cell carcinoma
Axicabtagene ciloleucel (Yescarta®)	TA872 - Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies TA894 - Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphoma TA895 - Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy
Axitinib	TA218 - Myelodysplastic syndromes - azacitidine	National CDF list
Azacitidine (Vidaza®)	TA827: Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy	For hospital use only
Baricitinib (Olumiant®)	TA466 - Baricitinib for moderate to severe rheumatoid arthritis	Hospital use only
Baricitinib (Olumiant®)#Chapter13	TA681 - Baricitinib for treating moderate to severe atopic dermatitis
Beclometasone CFC free MDI (QVAR brand)	TA138 - Asthma (in adults) - corticosteroids	For existing patients only

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports